<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2486">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04433546</url>
  </required_header>
  <id_info>
    <org_study_id>PB1046-PT-CL-0007</org_study_id>
    <nct_id>NCT04433546</nct_id>
  </id_info>
  <brief_title>Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).</brief_title>
  <acronym>VANGARD</acronym>
  <official_title>A Randomized, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of Once Weekly Subcutaneous Injections of Pemziviptadil (PB1046), a Sustained-Release VIP (Vasoactive Intestinal Peptide) ANalogue, in Hospitalized COVID-19 Patients at HiGh Risk for Rapid Clinical Deterioration and ARDS (PB1046 VANGARD Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PhaseBio Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PhaseBio Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, parallel group study to investigate the
      efficacy of pemziviptadil (PB1046) by improving the clinical outcomes and increasing days
      alive and free of respiratory failure in hospitalized COVID-19 patients at high risk for
      rapid clinical deterioration, acute respiratory distress syndrome (ARDS) and death.

      The study will enroll approximately 210 hospitalized COVID-19 patients who require urgent
      decision-making and treatment at approximately 20 centers in the United States.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will consist of a Screening/Pre-treatment period, on-site randomization to study
      treatment. On Day 0 (Visit 2) subjects who meet inclusion criteria and none of exclusion
      criteria will receive a weekly subcutaneous injection that will continue once weekly until
      hospital discharge or for a maximum of 4 weeks during hospitalization.

      All subjects will be randomized to either a low control (10 mg), middle (40 mg), or high (100
      mg) dose of active treatment. If subject is not discharged, they will continue to Day 7, 14,
      21 treatments. Pemziviptadil (PB1046) is expected to improve the clinical outcomes of
      hospitalized COVID-19 subjects with longer survival free from respiratory failure at 28 day.

      The duration of hospitalization for each subject will be determined by clinical status
      independent of study procedures. The estimated duration of the study for each subject,
      including screening, is approximately 35+7 days. The subjects may be involved up to 42 days.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2020</start_date>
  <completion_date type="Anticipated">December 18, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 18, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Days alive and free of respiratory failure from initiation of pemziviptadil (PB1046)</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to clinical recovery (being well enough for hospital discharge or returning to normal baseline activity level prior to discharge)</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of ARDS (PaO2:FiO2 ratio &lt; 300 mm Hg) during hospitalization</measure>
    <time_frame>Any time point between injection initiation and Day 28</time_frame>
    <description>PaO2:FiO2 ratio is the ratio of partial pressure of arterial oxygen to percentage of inspired oxygen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in hospital resource utilization defined as a composite of:total days: in hospital, in ICU, on ventilator, on ECMO, with invasive hemodynamic monitoring, with mechanical circulatory support, and with inotropic or vasopressor therapy</measure>
    <time_frame>28 days</time_frame>
    <description>Composite of: Total hospital days, Total ICU days, Total days of ventilator use, Total days of ECMO, Total days of invasive hemodynamic monitoring, Total days of mechanical circulatory support, Total days of inotropic or vasopressor therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical improvement as defined by reduction of at least 2 points on an 8-category ordinal scale of clinical improvement or discharge from hospital, whichever comes first.</measure>
    <time_frame>Any time point between injection initiation and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cardiac marker high sensitivity troponin I (hsTnI)</measure>
    <time_frame>Any time point between injection initiation and Day 35+7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cardiac marker NT-proBNP</measure>
    <time_frame>Any time point between injection initiation and Day 35+7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in TNF alpha</measure>
    <time_frame>Any time point between injection initiation and Day 35+7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in IL-1</measure>
    <time_frame>Any time point between injection initiation and Day 35+7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in IL-6</measure>
    <time_frame>Any time point between injection initiation and Day 35+7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of any treatment emergent adverse events (TEAEs) or serious adverse events (SAEs) as determined by clinical adverse events (AEs) and their relationship to PB1046</measure>
    <time_frame>Any time point between injection initiation and Day 35+7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of any treatment emergent adverse events (TEAEs) or serious adverse events (SAEs) as determined by vital signs and their relationship to PB1046</measure>
    <time_frame>Any time point between injection initiation and Day 35+7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of any treatment emergent adverse events (TEAEs) or serious adverse events (SAEs) as determined by laboratory results and their relationship to PB1046</measure>
    <time_frame>Any time point between injection initiation and Day 35+7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of any treatment emergent adverse events (TEAEs) or serious adverse events (SAEs) as determined by electrocardiogram (ECG) abnormalities and their relationship to PB1046</measure>
    <time_frame>Any time point between injection initiation and Day 35+7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of any treatment emergent adverse events (TEAEs) or serious adverse events (SAEs) as determined by incidence of anti-drug antibodies and their relationship to PB1046</measure>
    <time_frame>Any time point between injection initiation and Day 35+7</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Impact on invasive hemodynamic parameters as measured by pulmonary artery pressure if patients require right-heart catherization</measure>
    <time_frame>Any time point between injection initiation and Day 35+7</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Impact on invasive hemodynamic parameters as measured by cardiac output if patients require right-heart catherization</measure>
    <time_frame>Any time point between injection initiation and Day 35+7</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of multi-system organ failure (MSOF)</measure>
    <time_frame>Any time point between injection initiation and Day 35+7</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of multi-system organ failure (MSOF) free days</measure>
    <time_frame>Any time point between injection initiation and Day 35+7</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of subjects requiring extracorporeal membrane oxygenation (ECMO)</measure>
    <time_frame>Any time point between injection initiation and Day 35+7</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <condition>Coronavirus</condition>
  <condition>Hypoxic Respiratory Failure</condition>
  <condition>Hypoxemic Respiratory Failure</condition>
  <condition>Respiratory Complication</condition>
  <condition>Respiratory Insufficiency</condition>
  <condition>Cardiac Dysfunction</condition>
  <condition>Pneumonia</condition>
  <condition>Pulmonary Edema</condition>
  <condition>Pulmonary Inflammation</condition>
  <condition>Respiratory Failure</condition>
  <condition>Cytokine Storm</condition>
  <condition>COVID 19</condition>
  <condition>SARS-CoV-2</condition>
  <condition>Cardiac Event</condition>
  <condition>Cardiac Complication</condition>
  <condition>Cardiac Failure</condition>
  <condition>Cardiac Infarct</condition>
  <arm_group>
    <arm_group_label>High Dose (100 mg) Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High: Pemziviptadil (PB1046) 100 mg subcutaneous (SC) weekly for 4 weeks or until hospital discharge</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Middle Dose (40 mg) Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Middle: Pemziviptadil (PB1046) 40 mg SC weekly for 4 weeks or until hospital discharge</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose (10 mg) Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Low Control: Pemziviptadil (PB1046) 10 mg SC weekly for 4 weeks or until hospital discharge</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemziviptadil (PB1046)</intervention_name>
    <description>Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection</description>
    <arm_group_label>High Dose (100 mg) Group</arm_group_label>
    <arm_group_label>Middle Dose (40 mg) Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Dose (10 mg) Control</intervention_name>
    <description>Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection (10 mg diluted in sodium chloride to match active drug volume)</description>
    <arm_group_label>Low Dose (10 mg) Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written or witnessed verbal informed consent from patient or remote legal authorized
             representative (LAR) or remote family member as permitted by governing local or
             central Institutional Review Board (IRB)/independent Ethic Committee (IEC).

          2. Male or female 18-85 years old hospitalized COVID-19 patients (positive local
             SARS-CoV2 test)

          3. Receiving oxygen (O2) by face mask or nasal cannula/prongs and/or with elevated
             markers of cardiac injury or dysfunction (hsTnI or NT-proBNP) as assessed by local
             testing

        Exclusion Criteria:

        Subjects will be excluded from the study if they meet any of the following criteria:

          1. Patients considered unsalvageable or expected to expire within 24 hours

          2. On mechanical ventilation or imminent need for mechanical ventilation expected in the
             next 24 hours

          3. Evidence of acute end-organ injury in 2 or more organ systems (not including cardiac
             or pulmonary), such as, renal, hepatic, or CNS injury

          4. Receiving another investigational therapy for treatment or prevention of
             COVID-19-related hypoxemic respiratory failure or ARDS other than antiviral therapy

          5. Systolic blood pressure (SBP) &lt; 95 mmHg and/or diastolic blood pressure (DBP) &lt; 50
             mmHg or overt symptomatic hypotension during screening

          6. Resting heart rate &gt; 110 BPM (beats per minute) during screening

          7. Severe chronic renal failure as measured by the estimated glomerular filtration rate
             (eGFR) of &lt; 30 mL/min/1.73m2 using the local laboratory calculation of eGFR.

          8. Significant liver dysfunction as measured by any one of the following at screening:

               -  ALT (Alanine transaminase) &gt; 3.0 times ULN (upper limit of normal)

               -  AST (Aspartate transaminase) &gt; 3.0 times ULN

               -  Serum bilirubin â‰¥ 1.6 mg/dL

          9. Any in-patient surgical procedure or hospitalization (defined as &gt; 23 hours) within 30
             days of subject screening except for prior hospitalization for COVID-19

         10. Known hypersensitivity to study drug or any of the excipients of the drug formulation

         11. Pregnant or lactating female subjects

         12. Any other condition which, in the opinion of the Investigator, would place the subject
             at increased risk or would preclude obtaining informed consent or confound the
             objectives of study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Trials</last_name>
    <phone>888-521-2805</phone>
    <email>Clinicaltrials@phasebio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Baptist Health Research Institute</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Palaniswamy Vijay, MD</last_name>
      <phone>904-202-7069</phone>
      <email>Palaniswamy.Vijay@bmcjax.com</email>
    </contact>
    <investigator>
      <last_name>Juan D. Pulido, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarasota Memorial Hospital</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamela Fonseca</last_name>
      <phone>941-917-2225</phone>
      <email>Tamela-fonseca@smh.com</email>
    </contact>
    <investigator>
      <last_name>Kirk Voelker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luigi Boccardi</last_name>
      <phone>913-588-4022</phone>
      <email>lboccardi@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Leslie A Spikes, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Adventist Healthcare White Oak Medical Center</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Catanzaro, MD</last_name>
      <phone>301-891-6000</phone>
      <email>ACatanza@adventisthealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Andrew Catanzaro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>May 28, 2020</study_first_submitted>
  <study_first_submitted_qc>June 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2020</study_first_posted>
  <last_update_submitted>October 2, 2020</last_update_submitted>
  <last_update_submitted_qc>October 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Respiratory Distress Syndrome (ARDS)</keyword>
  <keyword>Respiratory distress/failure</keyword>
  <keyword>COVID</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Pulmonary Edema</mesh_term>
    <mesh_term>Pulmonary Valve Insufficiency</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Clinical Deterioration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

